$BIOLQ
BIOLASE, INC

2014 Q1 Form 10-Q Financial Statement

#000156459014002044 Filed on May 12, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q4 2013 Q1
Revenue $11.52M $15.24M $14.60M
YoY Change -21.09% -20.13% 18.48%
Cost Of Revenue $7.577M $9.030M $8.803M
YoY Change -13.93% -11.38% 35.16%
Gross Profit $3.941M $6.220M $5.794M
YoY Change -31.98% -30.03% -0.22%
Gross Profit Margin 34.22% 40.81% 39.69%
Selling, General & Admin $7.538M $7.200M $7.499M
YoY Change 0.52% 7.95% 20.2%
% of Gross Profit 191.27% 115.76% 129.43%
Research & Development $973.0K $1.040M $1.005M
YoY Change -3.18% 0.97% -15.55%
% of Gross Profit 24.69% 16.72% 17.35%
Depreciation & Amortization $175.0K $160.0K $145.0K
YoY Change 20.69% 14.29% 16.0%
% of Gross Profit 4.44% 2.57% 2.5%
Operating Expenses $8.576M $8.240M $8.611M
YoY Change -0.41% 7.01% 15.91%
Operating Profit -$4.635M -$2.020M -$2.817M
YoY Change 64.54% -269.75% 73.67%
Interest Expense -$230.0K -$190.0K -$87.00K
YoY Change 164.37% 35.71% 2075.0%
% of Operating Profit
Other Income/Expense, Net -$228.0K -$186.0K
YoY Change 22.58% 785.71%
Pretax Income -$4.863M -$2.220M -$3.003M
YoY Change 61.94% -309.43% 82.78%
Income Tax $24.00K $20.00K -$372.0K
% Of Pretax Income
Net Earnings -$4.887M -$2.230M -$2.631M
YoY Change 85.75% -314.42% 57.36%
Net Earnings / Revenue -42.43% -14.63% -18.02%
Basic Earnings Per Share -$0.13 -$0.08
Diluted Earnings Per Share -$0.13 -$329.4K -$0.08
COMMON SHARES
Basic Shares Outstanding 36.46M 32.17M
Diluted Shares Outstanding 36.46M 32.17M

Balance Sheet

Concept 2014 Q1 2013 Q4 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.840M $1.440M $1.230M
YoY Change 49.59% -43.31% -55.6%
Cash & Equivalents $1.835M $1.440M $1.229M
Short-Term Investments
Other Short-Term Assets $1.290M $1.910M $1.640M
YoY Change -21.34% 23.23% 41.38%
Inventory $11.89M $11.38M $11.92M
Prepaid Expenses
Receivables $8.560M $11.13M $10.64M
Other Receivables $0.00 $85.00K $0.00
Total Short-Term Assets $23.57M $25.85M $25.43M
YoY Change -7.32% -3.95% 9.33%
LONG-TERM ASSETS
Property, Plant & Equipment $1.750M $1.826M $1.616M
YoY Change 8.29% 21.01% 20.6%
Goodwill $2.926M $2.926M
YoY Change 0.0%
Intangibles $183.0K $254.0K
YoY Change -39.0%
Long-Term Investments
YoY Change
Other Assets $247.0K $249.0K $282.0K
YoY Change -12.41% -18.36% 41.0%
Total Long-Term Assets $5.087M $5.184M $5.093M
YoY Change -0.12% 2.53% 10.0%
TOTAL ASSETS
Total Short-Term Assets $23.57M $25.85M $25.43M
Total Long-Term Assets $5.087M $5.184M $5.093M
Total Assets $28.66M $31.04M $30.52M
YoY Change -6.12% -2.92% 9.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.776M $8.560M $8.708M
YoY Change -10.7% 11.71% 15.8%
Accrued Expenses $4.941M $4.997M $4.879M
YoY Change 1.27% -20.26% -10.31%
Deferred Revenue
YoY Change
Short-Term Debt $2.880M $4.630M $3.260M
YoY Change -11.66% 182.32%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.02M $21.94M $20.26M
YoY Change -6.11% 13.23% 33.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $34.00K
YoY Change -100.0% -100.0% -78.75%
Total Long-Term Liabilities $0.00 $0.00 $34.00K
YoY Change -100.0% -100.0% -78.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.02M $21.94M $20.26M
Total Long-Term Liabilities $0.00 $0.00 $34.00K
Total Liabilities $19.65M $22.56M $20.85M
YoY Change -5.73% 11.78% 30.38%
SHAREHOLDERS EQUITY
Retained Earnings -$128.6M -$123.8M -$114.9M
YoY Change 11.96% 10.23%
Common Stock $40.00K $148.9M $34.00K
YoY Change 17.65% 437852.94%
Preferred Stock
YoY Change
Treasury Stock (at cost) $16.40M $16.40M $16.40M
YoY Change 0.0% 0.0%
Treasury Stock Shares $1.964M $1.964M 1.964M shares
Shareholders Equity $9.005M $8.481M $9.677M
YoY Change
Total Liabilities & Shareholders Equity $28.66M $31.04M $30.52M
YoY Change -6.12% -2.92% 9.44%

Cashflow Statement

Concept 2014 Q1 2013 Q4 2013 Q1
OPERATING ACTIVITIES
Net Income -$4.887M -$2.230M -$2.631M
YoY Change 85.75% -314.42% 57.36%
Depreciation, Depletion And Amortization $175.0K $160.0K $145.0K
YoY Change 20.69% 14.29% 16.0%
Cash From Operating Activities -$2.800M -$2.210M -$2.822M
YoY Change -0.78% -216.32% 375.89%
INVESTING ACTIVITIES
Capital Expenditures $86.00K -$220.0K $139.0K
YoY Change -38.13% 144.44% -47.74%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0%
Cash From Investing Activities -$90.00K -$220.0K -$149.0K
YoY Change -39.6% 100.0% -43.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.280M -310.0K 1.700M
YoY Change 92.94% -43.64% 513.72%
NET CHANGE
Cash From Operating Activities -2.800M -2.210M -2.822M
Cash From Investing Activities -90.00K -220.0K -149.0K
Cash From Financing Activities 3.280M -310.0K 1.700M
Net Change In Cash 390.0K -2.740M -1.271M
YoY Change -130.68% -244.21% 118.38%
FREE CASH FLOW
Cash From Operating Activities -$2.800M -$2.210M -$2.822M
Capital Expenditures $86.00K -$220.0K $139.0K
Free Cash Flow -$2.886M -$1.990M -$2.961M
YoY Change -2.53% -200.0% 244.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
4633000
CY2013Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
617000
CY2013Q4 us-gaap Liabilities
Liabilities
22557000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
16399000
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1964000
CY2014Q1 us-gaap Liabilities
Liabilities
19652000
CY2014Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2878000
CY2014Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
165000
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
249000
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
247000
CY2014Q1 us-gaap Assets
Assets
28657000
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37626000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28657000
CY2014Q1 us-gaap Customer Deposits Current
CustomerDepositsCurrent
150000
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3275000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19020000
CY2013Q1 us-gaap Gross Profit
GrossProfit
5794000
CY2013Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5252000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2247000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1005000
CY2013Q1 biol Excise Tax
ExciseTax
107000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
8611000
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
183000
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2014Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
632000
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q1 biol Products And Services Revenue
ProductsAndServicesRevenue
11479000
CY2013Q1 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
108000
CY2013Q1 us-gaap Sales Revenue Net
SalesRevenueNet
14597000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
9005000
CY2014Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
807000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7776000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8560000
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4941000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4997000
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31038000
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Assets
Assets
31038000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
8481000
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
573000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1000
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37336000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35372000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21939000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3464000
CY2013Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
285000
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39590000
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
11518000
CY2014Q1 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
39000
CY2014Q1 us-gaap Gross Profit
GrossProfit
3941000
CY2014Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4455000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3083000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
973000
CY2014Q1 biol Stockholders Equity Excluding Treasury Stock
StockholdersEquityExcludingTreasuryStock
25404000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-372000
CY2013Q4 biol Stockholders Equity Excluding Treasury Stock
StockholdersEquityExcludingTreasuryStock
24880000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-2631000
CY2014Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
40000
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
154274000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
148866000
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-273000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-274000
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128637000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123750000
CY2014Q1 us-gaap Treasury Stock Value
TreasuryStockValue
16399000
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-99000
CY2013Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-87000
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-186000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4886000
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36455000
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32167000
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36455000
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32167000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
175000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
145000
CY2014Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
1964000
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7577000
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8803000
CY2014Q1 biol Excise Tax
ExciseTax
65000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
8576000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4635000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2817000
CY2014Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2000
CY2014Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-230000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-228000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4863000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3003000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-4887000
CY2013Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-56000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2687000
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2014Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
CY2014Q1 biol Provision Recoveries For Doubtful Accounts
ProvisionRecoveriesForDoubtfulAccounts
268000
CY2013Q1 biol Provision Recoveries For Doubtful Accounts
ProvisionRecoveriesForDoubtfulAccounts
-11000
CY2014Q1 us-gaap Inventory Write Down
InventoryWriteDown
261000
CY2014Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
120000
CY2013Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
18000
CY2014Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
57000
CY2013Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
38000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
310000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
368000
CY2013Q1 biol Other Equity Instruments Compensation
OtherEquityInstrumentsCompensation
64000
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-61000
CY2013Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-62000
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15000
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-107000
CY2014Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
12000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2301000
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1047000
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
774000
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
779000
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2000
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-23000
CY2014Q1 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-135000
CY2013Q1 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-304000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-392000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-659000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-190000
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-96000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2797000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2822000
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
139000
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2013Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-85000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-149000
CY2014Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
7570000
CY2013Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
8350000
CY2014Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
9325000
CY2013Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
6726000
CY2014Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
10000
CY2013Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1755000
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1594000
CY2014Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1025000
CY2014Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1366000
CY2014Q1 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4793000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
248000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
395000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1314000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2543000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1229000
CY2014Q1 us-gaap Interest Paid
InterestPaid
67000
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1700000
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
1000
CY2013Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-43000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
341000
CY2012Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1699000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3276000
CY2013Q1 us-gaap Interest Paid
InterestPaid
31000
CY2014Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5000
CY2013Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
45000
CY2013Q1 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1755000
CY2013Q1 us-gaap Product Warranty Expense
ProductWarrantyExpense
281000
CY2013Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
CY2014Q1 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
1645000
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </font></p><p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, indefinite-lived intangible assets, and the ability of goodwill to be realized, revenue deferrals for multiple element arrangements, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. </font></p></div>
CY2014Q1 biol Recent Accounting Pronouncements Policy Text B Lock
RecentAccountingPronouncementsPolicyTextBLock
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </font></p><p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Changes to U.S. GAAP are established by the Financial Accounting Standards Board (&#8220;FASB&#8221;) in the form of accounting standards updates (&#8220;ASU&#8217;s&#8221;) to the FASB&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;). </font></p><p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The Company considers the applicability and impact of all ASU&#8217;s. ASU&#8217;s not listed below were assessed and determined to not be applicable or are expected to have minimal impact on the Company&#8217;s consolidated financial position and results of operations. </font></p></div>
CY2014Q1 biol Working Capital
WorkingCapital
4600000
CY2014Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
2100000
CY2014Q1 biol Number Revolving Credit Facility Agreements
NumberRevolvingCreditFacilityAgreements
2
CY2014Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
5000000
CY2014Q1 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2014-05-01
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1945525
CY2014Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.57
CY2014Q1 biol Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
5000000
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
208000
CY2014Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
1300000
CY2014Q1 biol Proposed Maximum Aggregate Offering Price
ProposedMaximumAggregateOfferingPrice
12500000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
310000
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
368000
CY2014Q1 biol Share Based Compensation Net Impact On Earning Per Share Basic
ShareBasedCompensationNetImpactOnEarningPerShareBasic
-0.01
CY2013Q1 biol Share Based Compensation Net Impact On Earning Per Share Basic
ShareBasedCompensationNetImpactOnEarningPerShareBasic
-0.01
CY2013Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
428000
CY2014Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
517000
CY2013Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1096000
CY2014Q1 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
148000
CY2013Q1 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
337000
CY2014Q1 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1025000
CY2014Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
CY2014Q1 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
-0.01
CY2013Q1 biol Share Based Compensation Net Impact On Earning Per Share Diluted
ShareBasedCompensationNetImpactOnEarningPerShareDiluted
-0.01
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2200000
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y7M6D
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y8M12D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9837
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9270
CY2014Q1 biol Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend
0.00
CY2013Q1 biol Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividend
0.00
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0080
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4441000
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
116000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
244000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4394000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2666000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
85000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.51
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.14
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.71
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.50
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.50
CY2014Q1 biol Share Based Compensation Arrangements By Share Based Payment Award Options Expired Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredVestedWeightedAverageExercisePrice
5.13
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y9M29D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y7M13D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y10M28D
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1574000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
717000
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
678000
CY2014Q1 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
CY2013Q1 us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
82000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
23000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.86
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.84
CY2014Q1 biol Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodFairValue
346000
CY2013Q1 biol Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodFairValue
314000
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5998000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5060000
CY2014Q1 us-gaap Policyholder Dividends Rate On Policy Earnings
PolicyholderDividendsRateOnPolicyEarnings
0.02
CY2014Q1 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2014-03-14
CY2014Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
2850000
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3094000
CY2014Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1759000
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1727000
CY2014Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7282000
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6557000
CY2014Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3000000
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2800000
CY2014Q1 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8670000
CY2013Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
8598000
CY2014Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7120000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6971000
CY2014Q1 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1550000
CY2013Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1627000
CY2014Q1 us-gaap Land
Land
199000
CY2013Q4 us-gaap Land
Land
199000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
157000
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
99000
CY2014Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18000
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46000
CY2014Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2014Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2635000
CY2014Q1 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2617000
CY2013 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
CY2014Q1 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
Indefinite life
CY2013Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1898000
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1096000
CY2014Q1 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
163000
CY2013Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
322000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
912000
CY2014Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
276000
CY2014Q1 us-gaap Product Warranty Expense
ProductWarrantyExpense
219000
CY2013Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
1823000
CY2014Q1 biol Undelivered Elements Extended Warranty Current
UndeliveredElementsExtendedWarrantyCurrent
1630000
CY2013Q4 biol Undelivered Elements Extended Warranty Current
UndeliveredElementsExtendedWarrantyCurrent
1642000
CY2014Q1 us-gaap Deferred Revenue
DeferredRevenue
3275000
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
3465000
CY2013Q4 biol Undelivered Elements Extended Warranty Noncurrent
UndeliveredElementsExtendedWarrantyNoncurrent
1000
CY2014Q1 us-gaap Debt Issuance Costs
DebtIssuanceCosts
10000
CY2014Q1 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
2900000
CY2014Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
12000
CY2013Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
20000
CY2014Q1 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
57000
CY2013Q1 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
38000
CY2014Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2014Q1 biol Commitment Fees And Legal Costs Incurred
CommitmentFeesAndLegalCostsIncurred
10000
CY2013Q1 biol Commitment Fees And Legal Costs Incurred
CommitmentFeesAndLegalCostsIncurred
0
CY2014Q1 biol Financed Insurance Premium Payable
FinancedInsurancePremiumPayable
123000
CY2014Q1 us-gaap Short Term Debt Description
ShortTermDebtDescription
Nine
CY2014Q1 biol Financed Insurance Premium Finance Charge
FinancedInsurancePremiumFinanceCharge
0.0285
CY2014Q1 us-gaap Interest Expense Other
InterestExpenseOther
1000
CY2013Q1 us-gaap Interest Expense Other
InterestExpenseOther
2000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
516000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
204000
CY2014Q1 biol Change In Control Employee Severance
ChangeInControlEmployeeSeverance
567000
CY2014Q1 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
12200000
CY2013 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
250000
CY2014Q1 biol Sales To Customers Located Within United States
SalesToCustomersLocatedWithinUnitedStates
0.58
CY2013Q1 biol Sales To Customers Located Within United States
SalesToCustomersLocatedWithinUnitedStates
0.62
CY2014Q1 biol Sales To Customers Located Outside Of United States
SalesToCustomersLocatedOutsideOfUnitedStates
0.42
CY2013Q1 biol Sales To Customers Located Outside Of United States
SalesToCustomersLocatedOutsideOfUnitedStates
0.38
CY2014Q1 biol No Individual Country Other Than United States Represents More Than Ten Percentage Of Net Revenue
NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue
No individual country, other than the United States, represented more than 10% of total net revenue.
CY2013Q1 biol No Individual Country Other Than United States Represents More Than Ten Percentage Of Net Revenue
NoIndividualCountryOtherThanUnitedStatesRepresentsMoreThanTenPercentageOfNetRevenue
No individual country, other than the United States, represented more than 10% of total net revenue.
CY2014Q1 biol Entity Wide Revenue Major Customer Number
EntityWideRevenueMajorCustomerNumber
0
CY2013Q1 biol Entity Wide Revenue Major Customer Number
EntityWideRevenueMajorCustomerNumber
0
CY2014Q1 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
Less than 10%
CY2013Q1 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
Less than 10%
CY2014Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2013Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2014Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0054
CY2014Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34

Files In Submission

Name View Source Status
0001564590-14-002044-index-headers.html Edgar Link pending
0001564590-14-002044-index.html Edgar Link pending
0001564590-14-002044.txt Edgar Link pending
0001564590-14-002044-xbrl.zip Edgar Link pending
biol-10q_20140331.htm Edgar Link pending
biol-20140331.xml Edgar Link completed
biol-20140331.xsd Edgar Link pending
biol-20140331_cal.xml Edgar Link unprocessable
biol-20140331_def.xml Edgar Link unprocessable
biol-20140331_lab.xml Edgar Link unprocessable
biol-20140331_pre.xml Edgar Link unprocessable
biol-ex10_20140331342.htm Edgar Link pending
biol-ex10_20140331343.htm Edgar Link pending
biol-ex31_20140331214.htm Edgar Link pending
biol-ex31_20140331215.htm Edgar Link pending
biol-ex32_20140331216.htm Edgar Link pending
biol-ex32_20140331217.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending